IPSEN (OTCMKTS:IPSEY) Receives Consensus Rating of “Hold” from Brokerages

IPSEN (OTCMKTS:IPSEY) has earned an average rating of “Hold” from the six analysts that are presently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and two have issued a buy recommendation on the company.

IPSEY has been the subject of several research analyst reports. Jefferies Financial Group cut IPSEN from a “hold” rating to a “moderate sell” rating in a report on Sunday, August 2nd. Zacks Research upgraded IPSEN to a “hold” rating in a report on Friday, May 29th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of IPSEN in a report on Thursday, May 14th. Finally, HC Wainwright reiterated a “buy” rating on shares of IPSEN in a report on Tuesday, June 30th.

IPSEN Price Performance

OTCMKTS IPSEY opened at $47.60 on Thursday. IPSEN has a 1 year low of $32.02 and a 1 year high of $51.10. The business’s 50-day moving average is $46.06 and its 200 day moving average is $46.39.

IPSEN Company Profile

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).